Attitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks: A Survey of Patients, Nurses and Physicians

2021 ◽  
pp. 1-10
Author(s):  
Neta HaGani ◽  
Sharon Sznitman ◽  
Michael Dor ◽  
Gil Bar-Sela ◽  
Dana Oren ◽  
...  
Keyword(s):  
Side Effects ◽  
Medical Cannabis ◽  
Perceived Efficacy ◽  
Nurses And Physicians

scholarly journals What is associated with increased side effects and lower perceived efficacy following switching to a generic medicine? A New Zealand cross-sectional patient survey

BMJ Open ◽  
2018 ◽  
Vol 8 (10) ◽  
pp. e023667 ◽  
Author(s):  
Kate MacKrill ◽  
Keith J Petrie
Keyword(s):  
New Zealand ◽  
Side Effects ◽  
Generic Version ◽  
Drug Efficacy ◽  
Patient Survey ◽  
Generic Medicine ◽  
Cross Sectional Survey ◽  
Online Questionnaire ◽  
Cross Sectional ◽  
Perceived Efficacy

ObjectiveFollowing a switch from either a generic or branded antidepressant (venlafaxine) to a new generic, we investigated the factors associated with a preference for branded medicines, side effects reported following switching and efficacy ratings of the new generic drug.DesignA cross-sectional survey of patients switched to a new generic.SettingPatients accessing venlafaxine information online from the New Zealand government pharmaceuticals funding website.Participants310 patients, comprising 205 originally on branded venlafaxine and 105 previously taking a generic version.Main outcome measuresAn online questionnaire assessing demographic factors, perceived sensitivity to medicines, trust in pharmaceutical agencies, sources of switch information, preference for branded medicine, new medicine perceptions, side effects and efficacy ratings.ResultsPreference for branded medicine was significantly stronger in older patients (OR=1.04, 95% CI 1.01 to 1.05), those taking branded venlafaxine (OR=2.02, 95% CI 1.13 to 3.64) and patients with a higher perceived sensitivity to medicine (OR=1.23, 95% CI 1.06 to 1.19). Different factors predicted side effects in those switching from the branded and those switching from the generic venlafaxine. Trust in pharmaceutical agencies and the number of side effects were significant predictors of efficacy ratings of the new generic in both patients switching from a branded and those switching from a generic version of venlafaxine.ConclusionsIn patients switching from a branded medicine and those already taking a generic, different demographic and psychological factors are associated with preference for branded medicine, side effect reporting and perceived efficacy of the new drug. When switching to new generic, there appears to be a close bidirectional relationship between the experience of side effects and perceived drug efficacy. Trust in pharmaceutical agencies impacts directly on perceived efficacy and increasing such trust could reduce the nocebo response following a generic switch.

The Attitudes and Beliefs of Family Physicians Regarding the Use of Medical Cannabis, Knowledge of Side Effects, and Barriers to Use

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ramzi Abo Ziad ◽  
Mirta Beatriz Grynbaum ◽  
Roni Peleg ◽  
Yulia Treister-Goltzman
Keyword(s):  
Side Effects ◽  
Family Physicians ◽  
Attitudes And Beliefs ◽  
Medical Cannabis ◽  
Barriers To Use

scholarly journals Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Manuela Mazza
Keyword(s):  
Side Effects ◽  
Conventional Therapy ◽  
Fibromyalgia Syndrome ◽  
Rating Scale ◽  
Case Series ◽  
Depression Scale ◽  
Pain Clinic ◽  
Medical Cannabis ◽  
Paired Data ◽  
Oil Extract

Abstract Background The use of cannabis for treating fibromyalgia syndrome (FMS) has not been comprehensively investigated. Thus, we have assessed the efficacy and adverse events (AEs) of short- and long-term medical cannabis (MC) treatment for FMS. Methods Data were obtained from medical reports archived in the pain clinic of Ponderano (Italy; retrospective study). FMS patients, who were resistant to conventional therapy, received licensed MC with various Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) content, as powdered whole flowers (decoction or vaporization) or oil extracts. Demographic and clinical parameters, including Numerical Rating Scale (NRS), Oswestry Disability Index (ODI), Hospital Anxiety and Depression Scale, Widespread Pain Index (WPI), Severity Score (SyS), and side effects, were obtained after 1, 3, and 12 months. Data were analyzed with Wilcoxon signed-rank tests for paired data. Results Thirty-eight patients were included. Thirty, 18, and 12 patients continued therapy for 1, 3, and 12 months, respectively. Significant improvements (p < 0.01) were observed in NRS, ODI, WPI, and SyS at 1 month; in NRS, ODI, and WPI at 3 months; and in NRS, ODI, and SyS at 12 months. Therapy was interrupted by 17 patients (48.6%) owing to nonserious AEs according to the FDA. The most common side effects were mental confusion (37%), dizziness (14%), nausea/vomiting (14%), and restlessness/irritation (14%). The median daily dose of milled flowers administered as THC-dominant MC and hybrid MC (with similar THC/CBD ratio) was 200 mg/day and 400 mg/day, respectively. After 3 months of titration, the median content of THC administered with THC-dominant MC cultivars was 46.2 mg, and of THC + CBD administered as a hybrid MC cultivar, was 23.6 mg + 38 mg. At 3 months, median THC content administered in the oil extract of the THC-dominant MC cultivars was 9.7 mg, while that of THC + CBD administered in the oil extract of the hybrid MC cultivars was 1.8 mg + 2 mg. Conclusions MC may represent an alternative treatment for patients with FMS who are unresponsive to conventional therapy. However, its application may be limited by the incidence of nonserious AEs.

scholarly journals A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy

2016 ◽  
Vol 1 (1) ◽  
pp. 131-138 ◽  
Author(s):  
Michelle Sexton ◽  
Carrie Cuttler ◽  
John S. Finnell ◽  
Laurie K. Mischley
Keyword(s):  
Medical Cannabis ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Perceived Efficacy ◽  
Patterns Of Use

scholarly journals Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis

1988 ◽  
Vol 15 (1) ◽  
pp. 15-19 ◽  
Author(s):  
B. Bass ◽  
B. Weinshenker ◽  
G.P.A. Rice ◽  
J.H. Noseworthy ◽  
M.G.P. Cameron ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Effect ◽  
Side Effects ◽  
Muscle Weakness ◽  
Washout Period ◽  
Drug Withdrawal ◽  
Common Adverse Effect ◽  
Double Blind ◽  
Perceived Efficacy ◽  
Titration Period

ABSTRACT:Tizanidine (Sirdalud) was compared to baclofen (Lioresal) in a randomized, double-blind, cross-over trial. Each medication was introduced over a three week titration period and then maintained at the highest tolerated dose for five weeks. The two treatment phases were separated by a one week drug withdrawal and a two week washout period. Sixty-six patients entered the trial and forty-eight completed both treatment phases. At the end of the trial, neurologists and physiotherapists thought that baclofen was superior on the basis of perceived efficacy and tolerance (p≤0.05). Although the efficacy of tizanidine or baclofen was judged as good to excellent by 24 and 39% of patients respectively, this difference was not statistically significant. Muscle weakness was the most common adverse effect. This was significantly more troublesome in patients treated with baclofen. Somnolence and xerostomia were more common in patients treated with tizanidine. Both baclofen and tizanidine appear to be useful adjuncts in the treatment of spasticity in patients with multiple sclerosis. Preference of either drug is tempered principally by side-effects.

scholarly journals Cannabis, concussion, and chronic pain: An ongoing retrospective analysis at Dent Neurologic Institute in Buffalo, NY

Neurology ◽  
2018 ◽  
Vol 91 (23 Supplement 1) ◽  
pp. S18.3-S19 ◽  
Author(s):  
Jennifer McVige ◽  
Vincent Harry Bargnes ◽  
Said Shukri ◽  
Laszlo Mechtler
Keyword(s):  
Quality Of Life ◽  
New York ◽  
Chronic Pain ◽  
Side Effects ◽  
New York State ◽  
Activity Level ◽  
Average Dose ◽  
Medical Cannabis ◽  
Preliminary Results

ObjectiveTo examine medical cannabis (MC) as treatment for concussion-related chronic pain.Design/methodsIndividuals with concussion often experience chronic discomfort from headaches. MC treatment was approved for use in chronic pain by New York State in March 2017. DENT has treated 4,123 patients with MC, including 2,792 for chronic pain and 142 with concussion symptoms. Sixty-six charts were reviewed, with a total of 100 expected by presentation.Preliminary results(1) The Patient Global Impression of Improvement (PGI-I) scale revealed 80% of patients experienced significant improvement in activity level and symptoms. (2) Five common concussion symptoms (headache, mood, sleep, attention, and dizziness) were evaluated via modified-Likert scale (0 rated as “Much Worse” and 10 as “Much Better”). Moderate improvement (MI) was defined as 7–8 and significant improvement (SI) 9–10. Improvement was greatest in mood (63% MI, 20% SI), sleep (53% MI, 23% SI), and headache (60% MI, 14% SI). (3) Quality of Life after Brain Injury Score (QOLIBRI) scores were obtained on patients who had started MC (46) and those who had not yet (19). Comparison of the groups showed a significant improvement (p = 0.0035) in quality of life in individuals on MC. (4) The routes of administration that produced optimal benefit were 1:1 (THC:CBD) oral tincture at an average dose of 1.5 mL TID for prophylaxis and 20:1 vapor pen for acute pain. Together these products cost an average of $242 per month. (5) 15% of patients reported side effects, all minimal, with 63% related to administration route (poor taste, cough). No patients discontinued MC due to side effects.ConclusionsThese results support MC as an option for treatment of concussion-related chronic pain. While prospective studies are required, these preliminary results lay the foundation for investigating MC as a valid treatment for concussion and chronic pain.

Sign in / Sign up

Export Citation Format

Share Document